실시간
Eli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSNThermo FisherThe Bull Case For Thermo Fisher Scientific (TMO) Could Change Following AI-Enhanced Orbitrap Drug Discovery Launches – Learn Why - Yahoo Finance10x Genomics BlogThis $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - AOL.comEli LillyGilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - StocktwitsPfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord PharmaEndpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for VoyxactAgilentA Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus - simplywall.stBoston ScientificBoston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs - MassDeviceCharles RiverCharles River Laboratories stock (US1591881009): Insider grant and fresh fund buying keep focus on C - AD HOC NEWSEndpoints NewsActing FDA chief isn't interested in permanent roleClinical OMICsPost-Stroke Arm Immobility Improved with Spinal Cord StimulationLonza NewsStipple Bio and Lonza Agree to Focus on Advancing Oncology ADC Therapies - Genetic Engineering and Biotechnology News
Endpoints News 2025년 12월 10일

#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%

#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.